Lyra Therapeutics, Inc. 8-K

What Happened
Lyra Therapeutics, Inc. (LYRA) announced in a Form 8-K filed March 16, 2026 (Item 3.01) that it received a March 13, 2026 letter from the Nasdaq Hearings Advisor confirming the company has withdrawn its appeal of Nasdaq’s February 2, 2026 delisting determination. As a result of withdrawing the appeal, Nasdaq confirmed trading in Lyra’s common stock will be suspended at the open of trading on Tuesday, March 17, 2026. Nasdaq also indicated it will file a Form 25 Notification of Delisting with the SEC after all internal procedural periods have run.

Key Details

• Date of Nasdaq delisting determination: February 2, 2026.
• Date company received Nasdaq letter confirming withdrawal: March 13, 2026.
• Trading suspension effective: at the open on March 17, 2026.
• Nasdaq plans to file Form 25 (Notification of Delisting) with the SEC after internal procedures.

Why It Matters
A suspension of trading on Nasdaq means investors will not be able to buy or sell Lyra’s common stock on the Nasdaq exchange beginning March 17, 2026, and a subsequent Form 25 could lead to removal from the exchange. This affects share liquidity and market access for holders of LYRA stock; investors should monitor future company and Nasdaq filings for next steps and any alternative trading arrangements.